Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million

Jaguar Health, Inc.

Exclusive license to Future Pak for Mytesi (HIV/AIDS diarrhea) and Canalevia-CA1 (chemotherapy-induced diarrhea in dogs) in U.S.
Jaguar receives $18M upfront ($16M at closing + $2M on conditions) and up to $20M in milestone/future payments.
Jaguar retains manufacturing role; non-dilutive capital funds rare-disease pipeline (short bowel syndrome, MVID).
Jaguar has buy-back option after 5 years or upon FDA approval of additional crofelemer indications.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Jaguar Health, Inc. entered into License Agreement with Woodward Specialty LLC and Future Pak, LLC valued at $18 million (effective 2026-01-12).

Action: entry
Agreement: license
Counterparty: Woodward Specialty LLC and Future Pak, LLC
Value: $18 million
Effective: 2026-01-12

Exact text from the filing

On January 12, 2026 (the “Effective Date”), Napo Pharmaceuticals, Inc. (“Napo”), a wholly-owned subsidiary of Jaguar Health, Inc., a Delaware corporation (the “Company”), and the Company, entered into a license agreement (the “License Agreement”) with Woodward Specialty LLC (the “Licensee”), an affiliate of Future Pak, LLC (“Future Pak”), and Future Pak

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Jaguar Health, Inc. entered into Supply Agreement with Woodward Specialty LLC and Future Pak, LLC (effective 2026-01-12).

Action: entry
Agreement: supply
Counterparty: Woodward Specialty LLC and Future Pak, LLC
Effective: 2026-01-12

Exact text from the filing

Also on the Effective Date, Napo, Licensee and Future Pak entered into a manufacturing and supply agreement (the “Supply Agreement”)

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

Jaguar Health, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-014231

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.